Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- RNAi-Pathway Components and Mechanisms
-
1. Activation of gene expression by double-stranded RNAs
- Prof. Long-Cheng Li
-
2. MicroRNA biogenesis
- Dr. Narry Kim
-
3. Dicer and R2D2
- Dr. Young Sik Lee
-
4. Mammalian microRNA assembly and function
- Prof. Zissimos Mourelatos
-
5. Mechanisms of RNAi: a molecular view or Argonaute: the secret life of Slicer
- Prof. Leemor Joshua-Tor
- Roles for RNAi in Development and Anti-Viral Defense
-
6. Functional roles of RNAi in C. elegans
- Dr. Eric Miska
-
7. RNAi and heterochromatin in plants and fission yeast
- Prof. Robert Martienssen
-
8. RNA interference functions and mechanisms in animals
- Prof. Richard Carthew
-
9. Specific functional roles in mammals
- Dr. Michael McManus
- RNAi Design Rules for Applications in Humans
-
10. siRNA on and off-target
- Prof. Anastasia Khvorova
-
11. Cell signalling pathways and RNAi
- Mr. Michael O'Grady
-
12. RNAi: key technological aspects
- Dr. Dmitry Samarsky
- Dr. Ciaran Faherty
-
13. RNAi specificity: how big of an issue is it?
- Dr. Peter Welch
- Applications of RNAi in the Treatment of Human Diseases
-
14. siRNA therapeutics
- Prof. John Rossi
- Mr. Daniel J. Rossi
-
15. RNAi for neurological diseases
- Prof. Beverly L. Davidson
-
16. RNA interference and cancer: a revolution?
- Dr. Annick Harel-Bellan
- Archived Lectures *These may not cover the latest advances in the field
-
17. RNAi and viral heart infections
- Dr. Jens Kurreck
-
18. RNA interference for neurodegenerative diseases
- Prof. Beverly L. Davidson
-
19. Activation of gene expression by double-stranded RNA
- Prof. David Corey
-
20. New designs for siRNAs as Dicer substrate
- Dr. Mark Behlke
-
21. RNAi in the model system Drosophila
- Prof. Richard Carthew
-
23. Therapeutic delivery of RNAi
- Dr. Patrick Lu
-
24. Mechanistic aspects and therapeutic applications of RNAi
- Prof. John Rossi
Printable Handouts
Navigable Slide Index
- Introduction
- Polyglutamine (polyQ) repeat diseases
- Repeat expansion diseases (1)
- Repeat expansion diseases (2)
- Suppressing dominant disease genes
- How to accomplish reduction in expression?
- Reduction in expression by RNA interference
- A cartoon of the RNAi pathway
- Human spinocerebellar ataxia type 1 (SCA1)
- Effects of shSCA1 on mutant human ataxin-1 (1)
- Effects of shSCA1 on mutant human ataxin-1 (2)
- Testing shAtaxin1 in vivo: dendritic atrophy
- Testing shAtaxin1 in vivo: hSCA1 transgenics
- Testing shAtaxin1 in vivo: ataxia
- How to accomplish RNAi in target brain cells
- AAVs - deliver genetic material to the brain (1)
- AAVs - deliver genetic material to the brain (2)
- Testing shAtaxin1 in vivo: delivery issues
- shSCA1 and shLacZ transcripts in cerebellum
- shSCA1: impact on behavior
- Advantage of half-transduced lobules
- Photomicrographs from half-transduced lobules
- shSCA1 normalizes molecular layer widths
- shSCA1 reduces ataxin-1 aggregates
- Summary (1)
- Huntington's disease: a brief history
- Huntington's disease (HD)
- Mutant huntingtin expression downstream effects
- Designing shRNAs for huntingtin
- shHD2.1 reduces HD-N171-82Q mRNA
- shHD2.1 reduces HD-N171-82Q Protein
- Testing shHD in vivo
- shRNA delivery to mouse brain using AAV1
- shHD2.1 reduces transgene expression in vivo
- shHD2.1 reduces Htt-immunoreactive inclusions
- shHD2.1 improves rotarod performance in mice
- Gait abnormalities in HD mice
- shHD2.1 improves stride length in mice
- Summary (2)
- Acknowledgements
Topics Covered
- Brain diseases and molecular therapies
- RNA interference
- Mice models of brain disease
- Viral vectors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Davidson, B.L. (2007, October 1). RNA interference for neurodegenerative diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 25, 2024, from https://hstalks.com/bs/654/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Beverly L. Davidson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.